PolyMedix Presents Data Showing Antimicrobial Activity Of Sutures Containing PolyCide
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented data showing that its PolyCide ® materials are active as agents for use in antimicrobial sutures. PolyCides are synthetic antimicrobial compounds that mimic the mechanism of the host defense proteins and are being developed as additives to materials and products to make them self-sterilizing. The data was presented at the Association for Professionals in Infection Control (APIC) international meeting on June 27-29, 2011 in Baltimore, Maryland.
“There is a growing need for effective and safe alternatives to impart antimicrobial properties to medical devices,” commented, Nicholas Landekic, President and Chief Executive Officer of PolyMedix. “The currently available antimicrobial suture contains triclosan, an agent which has limited coverage and to which widespread resistance has been demonstrated. Our PolyCide biomaterials have a broad spectrum of activity and a unique mechanism of action designed to make bacterial resistance much less likely to develop. We believe that our PolyCide biomaterials could play an important role in reducing the incidence of surgical site infections, a potentially serious and expensive medical problem.”
The results, presented by Dr. Richard Scott, Vice President of Research at PolyMedix, demonstrated that the PolyCide compounds have broad spectrum activity against both Gram-positive and Gram-negative pathogens associated with surgical site infections, and have superior bacterial killing activity over triclosan and silver nitrate, another commonly used biocidal agent. Furthermore, no evidence for the development of resistance was observed with the PolyCide materials in laboratory serial passage assays, whereas resistance to triclosan was readily demonstrated.
“These data support our continued efforts to expand the use of our PolyCide compounds to other wound care applications and medical devices to improve infection control,” commented Dr. Scott. “We are excited about these results and the opportunities to develop the PolyCide materials for antimicrobial sutures.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts